Related Experiment Videos
Gene therapy for colorectal cancer
D J Kerr1, L W Seymour, F Maruta
1Department of Clinical Pharmacology, Radcliffe Infirmary, University of Oxford, Woodstock Road, Oxford, OX2 6HE, UK.
Abstract:
Colorectal cancer is an important public health problem worldwide. Gene therapy has therapeutic potential for patients with advanced or recurrent colorectal cancer, incurable by conventional treatments. To date, many strategies of gene therapy have been explored, including mutant gene correction, prodrug activation, immune stimulation and genetically-modified oncolytic viruses. Although the preclinical results of gene therapy for colorectal cancer have shown promise, gene therapy is still at an early stage of clinical development and has not yet shown a significant therapeutic benefit for patients. The main obstacles for introduction of gene therapy to patients are poor targeting selectivity of the vectors and inefficient gene transfer. As the science supporting tumour-selective vectors evolves, gene therapy may expand rapidly in the clinical practice of colorectal cancer treatment.
Insights
Gene therapy shows promise for advanced colorectal cancer, but faces challenges. Improved targeting and gene transfer are key for clinical success in treating this public health problem.
Area of Science:
- Oncology
- Molecular Biology
- Biotechnology
Background:
- Colorectal cancer (CRC) presents a significant global health challenge.
- Conventional treatments are often ineffective for advanced or recurrent CRC.
- Gene therapy offers a potential alternative for difficult-to-treat CRC cases.
Purpose of the Study:
- To review the current state and potential of gene therapy for colorectal cancer.
- To identify key strategies and challenges in CRC gene therapy.
- To discuss future directions for gene therapy in CRC treatment.
Main Methods:
- Exploration of various gene therapy strategies, including mutant gene correction, prodrug activation, immune stimulation, and oncolytic viruses.
- Review of preclinical and early clinical development findings.
- Analysis of obstacles hindering clinical application.
Main Results:
- Preclinical studies demonstrate promising results for gene therapy in CRC models.
- Current clinical development is in its early stages with limited therapeutic benefit observed.
- Key challenges include poor vector targeting selectivity and inefficient gene transfer.
Conclusions:
- Gene therapy holds significant potential for advanced or recurrent colorectal cancer.
- Overcoming vector targeting and gene transfer inefficiencies is crucial.
- Advancements in tumor-selective vectors could accelerate clinical adoption for CRC treatment.